Saturday 17 October 2026
Export AKAN’s income statement to Excel — free account
Akanda Corp.
AKAN Healthcare Drug Manufacturers Specialty & Generic
Akanda Corp.’s revenue for fiscal 2025 (year ended December 2025) was $258,100.00, down 69.2% from fiscal 2024. Insiders bought in the last twelve months.
1.20
0.11
−8.40%
Follow AKAN
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
EV/Sales |
— | — | — | — |
+7 more quarters Free account |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.19 | 0.31 | 1.24 | 1.28 | |
Current Ratio |
0.22 | 0.58 | 1.25 | 1.39 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
177.99% | 209.72% | 4.11% | 4.46% | |
Debt/Equity |
(0.70) | (1.08) | 0.08 | 0.08 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | (2.84) | 0.00 | (5.21) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
— | 0.00 | 0.00 | 0.00 | |
Capex per Share |
— | 0.00 | — | 0.00 | |
Free Cash Flow per Share |
— | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | (7.96) | (0.38) | (6.08) | |
Working Capital |
(9.68) | (2.60) | 0.72 | 1.42 | |
Capital Expenditures |
— | (1.23) | — | (2.10) | |
Net Current Asset Value |
(20.11) | (14.58) | 0.65 | 1.42 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Receivables |
0.98 | 0.84 | 0.83 | 1.03 | |
Average Payables |
3.67 | 4.66 | 5.33 | 5.06 | |
Average Assets |
8.20 | 7.52 | 21.36 | 23.46 | |
Average Common Equity |
(5.95) | (7.91) | 12.47 | 15.59 |
Columns are period end dates · fundamentals updated 2 Oct 2026